Rochester, NY 8/28/2009 11:12:24 PM
IsoRay Product for commercial distribution for treatment
IsoRay, Inc. ISR
IsoRay, Inc. announced today that it has received clearance from the FDA for its Premarket Notification, [510(k)] for Proxcelan Cesium-131 Brachytherapy Seeds enabling the company to preload Cesium-131 into flexible braided strands and surgical mesh. This FDA clearance allows IsoRay to market Cesium-131 seeds for use in the treatment of cancers well beyond the current prostate market.
This order clears the product for commercial distribution for treatment of lung and head and neck tumors as well as tumors in other organs. While Cesium-131 seeds themselves have been cleared for this indication since 2003, this current 510(k) allows Cesium-131 to be delivered in a new, convenient and sterile format that can be implanted without additional seed loading by the facility. The 510(k) also clears the application of the braided strands onto a bioabsorbable mesh matrix to further facilitate implant procedures.
About WhisperFromWallStreet
WhisperFromWallStreet.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified.
This is a free service available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://WhisperFromWallStreet.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither WhisperfromWallStreet, nor any of its affiliates are registered investment advisors or broker dealers.
